AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 271 min read$RCKT

ROCKET PHARMACEUTICALS, INC. (RCKT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Severance and Change in Control Program On August 21, 2026, the Board of Directors (the “Board”) of Rocket Pharmaceuticals

Original reporting
SEC EDGAR 8-K
Published Aug 27, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$RCKT
Neutral
medium confidence
Mentioned
$RCKT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The disclosure provides transparency on executive compensation but does not alter the company's financial outlook.

02

Market read

Primary corporate‑action filing with modest relevance for traders; unlikely to drive significant price action.

03

What to watch

The filing does not disclose any immediate compensation expense; the true cost will materialize only upon a qualifying termination.

Relevance 6/10Novelty 5/10Timing: effective August 21, 2026

Background

Rocket Pharmaceuticals filed a Form 8‑K on August 27, 2026, announcing a company‑wide severance program and updated executive contracts.

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

SEC 8‑K filing discloses a new severance and change‑in‑control program and updated executive employment agreements for Rocket Pharmaceuticals.

Expected impact

Limited short‑term price movement; any reaction likely muted unless investors view the terms as unusually generous.

Evidence & confidence

The filing is a primary corporate‑action disclosure, but the materiality is low for a micro‑cap biotech; no cash outlay or strategic shift is announced.

Market effects

Sector

May set a precedent for severance standards among small biotech firms, but sector impact is minimal.

Regional

U.S. biotech market; no broader regional effect.

Global

Limited to investors tracking Rocket Pharmaceuticals.

Counterpoint

What could challenge this read

Investors could view the generous severance terms as a red flag for potential future dilution or cash burn if a change‑in‑control event occurs.

Key entities

  • Executive
    Gaurav Shah

    Chief Executive Officer of Rocket Pharmaceuticals.

  • Executive
    Martin Wilson

    General Counsel and Chief Corporate Officer.

Read at source← All news

Related articles

SEP 4
$RCKTHighAI 9/10

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.

stocktwits.com2 min
SEP 2
$RCKTMedAI 8/10

Rocket amended complaint alleges UWM targeted Mr. Cooper borrowers

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

housingwire.com3 min
AUG 10
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

SEC EDGAR 8-K6 min
AUG 4
$RCKTMed

Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

yahoo.com5 min
AUG 3
$RCKTMed

Why is Rocket Pharmaceuticals stock volatile today?

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

investing.com3 min
JUN 12
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R

SEC EDGAR 8-K2 min